UA93306C2 - 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses - Google Patents

3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Info

Publication number
UA93306C2
UA93306C2 UAA200907945A UAA200907945A UA93306C2 UA 93306 C2 UA93306 C2 UA 93306C2 UA A200907945 A UAA200907945 A UA A200907945A UA A200907945 A UAA200907945 A UA A200907945A UA 93306 C2 UA93306 C2 UA 93306C2
Authority
UA
Ukraine
Prior art keywords
treatment
compound
substituted
synaptic responses
glutamatergic synaptic
Prior art date
Application number
UAA200907945A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Алексис Корди
Гари Роджерс
Рудольф Мюллер
Original Assignee
Koptekc Фармасьютикалз, Инк.
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koptekc Фармасьютикалз, Инк., Ле Лаборатуар Сервье filed Critical Koptekc Фармасьютикалз, Инк.
Publication of UA93306C2 publication Critical patent/UA93306C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias, and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to a compound useful for treatment of such conditions, and methods of using this compound for such treatment.
UAA200907945A 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses UA93306C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03

Publications (1)

Publication Number Publication Date
UA93306C2 true UA93306C2 (en) 2011-01-25

Family

ID=50829906

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907945A UA93306C2 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Country Status (1)

Country Link
UA (1) UA93306C2 (en)

Similar Documents

Publication Publication Date Title
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
SG163545A1 (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
EA201390971A1 (en) IMIDAZO [5,1-f] [1,2,4] TRIAZINS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
MX2011002705A (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2013025997A3 (en) Brain stimulation methods for treating central sensitivity
EA201071243A1 (en) COMBINED COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES WITH ZONISSMID AND ACAPROSAT
DE602006008456D1 (en) AMYLIN AND AMYL LAGONISTS FOR THE TREATMENT OF PSYCHIATRIC ILLNESSES AND DISORDERS
UY28817A1 (en) IMIDAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGERATIVE DISORDERS
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2008050341A3 (en) Novel psychotropic agents having glutamate nmda activity
WO2009158467A3 (en) Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
MX2010001824A (en) Heterocycles as potassium channel modulators.
EP2977452A3 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
WO2013029060A3 (en) Compositions and methods for treating neurodegenerative disease
JP2009537568A5 (en)
WO2003045315A3 (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
WO2008022155A3 (en) Methods of identifying agents for treating neurological disorders
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
UA93306C2 (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
IL196615A0 (en) N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EP2552473A4 (en) Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
MX2011008060A (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses.
EP4045149A4 (en) Regenerating functional neurons for treatment of neurological disorders